08-21-2006: Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. , announced a target validation collaboration with Schering-Plough Corporation, under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high value targets resulting from drug discovery research conducted by the Schering-Plough Research Institute.
SPCT evaluates the physiological and behavioral impact of such high value targets by utilizing a battery of more than 85 pharmacologically-validated challenge or bioassays (measuring over 400 individual parameters), and covering most therapeutic areas. The recently signed phenotypic characterization agreement expands on a previous gene targeting agreement aimed at the creation of standard and conditional gene knockouts, both of which contribute to a fuller understanding of the biological effects associated with the deletion of a gene's function. Financial terms of the deal were not disclosed.
OncoMethylome Sciences Expands its Collaboration with Schering-Plough
OncoMethylome Sciences announced that it has entered into a new non-exclusive service agreement with Schering-Plough. Under the terms of the new agreement, OncoMethylome will receive processing fees for providing Schering-Plough with testing services in connection with clinical trials focus ... more
Xenogen Biosciences Announces Target Validation Collaboration Agreement with Schering-Plough
Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. , announced a target validation collaboration with Schering-Plough Corporation, under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high ... more
Xenogen Biosciences Announces Target Validation Collaboration Agreement with Schering-Plough
Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. , announced a target validation collaboration with Schering-Plough Corporation, under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high ... more
Caliper Life Sciences and Xenogen Schedule Stockholder Meetings to Approve Merger
Caliper Life Sciences, Inc. and Xenogen Corporation announced that the S-4 registration statement-joint proxy statement for their previously announced pending merger was declared effective by the United States Securities and Exchange Commission on July 11, 2006, and that each company will h ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
